Dopamine D3 receptor Modulates l-DOPA-Induced Dyskinesia by Targeting D1 Receptor-Mediated Striatal Signaling

Cerebral Cortex

Volumn 27, Issue 1, 2017, Pages 435-446

  Solís, Oscar ^a,b   Garcia Montes, Jose Ruben ^a,b   González Granillo, Aldo ^a   Xu, Ming ^c   Moratalla, Rosario ^a,b  

^a INSTITUTO CAJAL   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Abnormal involuntary movements; Basal ganglia; Behavioral sensitization; Parkinson disease; Striatonigral

Indexed keywords

DOPAMINE 1 RECEPTOR; DOPAMINE 3 RECEPTOR; GREEN FLUORESCENT PROTEIN; HISTONE H3; LEVODOPA; MITOGEN ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR FOSB; DOPAMINE RECEPTOR STIMULATING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; BRAIN NERVE CELL; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE ASSOCIATION; DORSOLATERAL STRIATUM; DYSKINESIA; FEMALE; GENE OVEREXPRESSION; INTRACELLULAR SIGNALING; KNOCKOUT MOUSE; MALE; MOUSE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; ANIMAL; DRUG EFFECTS; METABOLISM; PARKINSONISM;

ANIMALS; CORPUS STRIATUM; DOPAMINE AGENTS; DYSKINESIA, DRUG-INDUCED; LEVODOPA; MICE; MICE, KNOCKOUT; PARKINSONIAN DISORDERS; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D3;

EID: 85016435519     PISSN: 10473211     EISSN: 14602199     Source Type: Journal    
DOI: 10.1093/cercor/bhv231     Document Type: Article

References (50)

1. Andersson M, Hilbertson A, Cenci MA. 1999. Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntarymovements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol Dis. 6:461-474.
2. Ares-Santos S, Granado N, Espadas I, Martinez-Murillo R, Moratalla R. 2014. Methamphetamine causes degeneration of dopamine cell bodies and terminals of the nigrostriatal pathway evidenced by silver staining. Neuropsychopharmacology. 39:1066-1080.
3. Beaulieu JM, Gainetdinov RR. 2011. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev. 63:182-217.
4. Berthet A, Porras G, Doudnikoff E, Stark H, Cador M, Bezard E, Bloch B. 2009. Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of L-DOPA-induced dyskinesia. J Neurosci. 29:4829-4835.
5. Bézard E, Ferry S, Mach U, Stark H, Leriche L, Boraud T, Gross C, Sokoloff P. 2003. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med. 9:762-767.
6. Bordet R, Ridray S, Carboni S, Diaz J, Sokoloff P, Schwartz JC. 1997. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc Natl Acad Sci. 94:3363-3367.
7. Bordet R, Ridray S, Schwartz JC, Sokoloff P. 2000. Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats. Eur J Neurosci. 12:2117-2123.
8. Cote SR, Chitravanshi VC, Bleickardt C, Sapru HN, Kuzhikandathil EV. 2014. Overexpression of the dopamine D3 receptor in the rat dorsal striatum induces dyskinetic behaviors. Behav Brain Res. 263:46-50.
9. Cruz-Trujillo R, Avalos-Fuentes A, Rangel-Barajas C, Paz-Bermúdez F, Sierra A, Escartín-Perez E, Aceves J, Erlij D, Florán B. 2013. D3 dopamine receptors interact with dopamine D1 but not D4 receptors in the GABAergic terminals of the SNr of the rat. Neuropharmacology. 67:370-378.
10. Darmopil S, Martín AB, De Diego IR, Ares S, Moratalla R. 2009. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation. Biol Psychiat. 66:603-613.
11. Farré D, Muñoz A, Moreno E, Reyes-Resina I, Canet-Pons J, Dopeso- Reyes IG, Rico AJ, Lluís C, Mallol J, Navarro G, et al. 2014. Stronger dopamine D1 receptor-mediated neurotransmission in dyskinesia. Mol Neurobiol. doi:10.1007/s12035-014-8936-x.
12. Fasano S, Bezard E, D'Antoni A, Francardo V, Indrigo M, Qin L, Doveró S, Cerovic M, Cenci MA, Brambilla R. 2010. Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with l-dopa-induced dyskinesia. Proc Natl Acad Sci. 107: 21824-21829.
13. Feyder M, Södersten E, Santini E, Vialou V, LaPlant Q, Watts EL, Spigolon G, Hansen K, Caboche J, Nestler EJ, et al. 2014. A role for mitogen- and stress-activated kinase 1 in L-DOPAinduced dyskinesia and ΔFosB expression. Biol Psychiatry. doi:10.1016/j.biopsych.2014.07.019.
14. Fiorentini C, Busi C, Gorruso E, Gotti C, Spano P, Missale C. 2008. Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization. Mol Pharmacol. 74:59-69.
15. Flores G, Barbeau D, Quirion R, Srivastava LK. 1996. Decreased binding of dopamine D3 receptors in limbic subregions after neonatal bilateral lesion of rat hippocampus. J Neurosci. 16:2020-2026.
16. González-Aparicio R, Moratalla R. 2014. Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinsońs disease. Neurobiol Dis. 62:416-425.
17. Granado N, Ares-Santos S, Oliva I, O'Shea E, Martin ED, Colado MI, Moratalla R. 2011. Dopamine D2-receptor knockout mice are protected against dopaminergic neurotoxicity induced by methamphetamine or MDMA. Neurobiol Dis. 42:391-403.
18. Grundt P, Carlson EE, Cao J, Bennett CJ, McElveen E, Taylor M, Luedtke RR, Newman AH. 2005. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl] butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor. J Med Chem. 48:839-848.
19. Grundt P, Prevatt KM, Cao J, Taylor M, Floresca CZ, Choi JK, Jenkins BG, Luedtke RR, Newman AH. 2007. Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents. J Med Chem. 50:4135-4146.
20. Guigoni C, Aubert I, Li Q, Gurevich VV, Benovic JL, Ferry S, Mach U, Stark H, Leriche L, Hakansson K, et al. 2005. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors. Parkinsonism Relat Dis. 11(Suppl 1):S25-S29.
21. Guillin O, Diaz J, Carroll P, Griffon N, Schwartz JC, Sokoloff P. 2001. BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature. 411:86-89.
22. Guitart X, Navarro G, Moreno E, Yano H, Cai NS, Sanchez-Soto M, Kumar-Barodia S, Naidu YT, Mallol J, Cortes A, et al. 2014. Functional selectivity of allosteric interactions within G protein- coupled receptor oligomers: the dopamine D1-D3 receptor heterotetramer. Mol Pharmacol. 86:417429.
23. Heiman M, Heilbut A, Francardo V, Kulicke R, Fenster RJ, Kolaczyk ED, Mesirov JP, Surmeier DJ, Cenci MA, Greengard P. 2014. Molecular adaptations of striatal spiny projection neurons during levodopa-induced dyskinesia. Proc Natl Acad Sci USA. 111:4578-4583.
24. Hope BT, Nye HE, Kelz MB, Self DW, Iadarola MJ, Nakabeppu Y, Duman RS, Nestler EJ. 1994. Induction of a long-lasting AP-1 complex composed of altered Fos-like proteins in brain by chronic cocaine and other chronic treatments. Neuron. 13:1235-1244.
25. Huot P, Johnston TH, Koprich JB, Aman A, Fox SH, Brotchie JM. 2012. L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Pharmacol Exp Ther. 342:576-585.
26. Jung MY, Schmauss C. 1999. Decreased c-fos responses to dopamine D(1) receptor agonist stimulation in mice deficient for D(3) receptors. J Biol Chem. 274:29406-29412.
27. Kumar R, Riddle L, Griffin SA, Grundt P, Newman AH, Luedtke RR. 2009. Evaluation of the D3 dopamine receptor selective antagonist PG01037 on L-dopa-dependent abnormal involuntary movements in rats. Neuropharmacology. 56:944-955.
28. Marcellino D, Ferré S, Casadó V, Cortés A, Le Foll B, Mazzola C, Drago F, Saur O, Stark H, Soriano A, et al. 2008. Identification of dopamine D1-D3 receptor heteromers. Indications for a role of synergistic D1-D3 receptor interactions in the striatum. J Biol Chem. 283:26016-26025.
29. Mason CW, Hassan HE, Kim KP, Cao J, Eddington ND, Newman AH, Voulalas PJ. 2010. Characterization of the transport, metabolism, and pharmacokinetics of the dopamine D3 receptor-selective fluorenyl- and 2-pyridylphenyl amides developed for treatment of psychostimulant abuse. J Pharmacol Experim Ther. 333:854-864.
30. Mela F, Millan MJ, Brocco M, Morari M. 2010. The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats. Neuropharmacology. 58:528-536.
31. Moratalla R, Elibol B, Vallejo M, Graybiel AM. 1996a. Network-level changes in expression of inducible Fos-Jun proteins in the striatum during chronic cocaine treatment and withdrawal. Neuron. 17:147-156.
32. Moratalla R, Vallejo M, Elibol B, Graybiel AM. 1996b. D1-class dopamine receptors influence cocaine-induced persistent expression of Fos-related proteins in striatum. Neuroreport. 8:1-5.
33. Murer MG, Moratalla R. 2011. Striatal signaling in L-DOPAinduced dyskinesia: common mechanisms with drug abuse and long term memory involving D1 dopamine receptor stimulation. Front Neuroanat. 5:51.
34. Obeso JA, Olanow CW, Nutt JG. 2000. Levodopa motor complications in Parkinson's disease. Trends Neurosci. 23:S2-S7.
35. Pavón N, Martín AB, Mendialdua A, Moratalla R. 2006. ERK Phosphorylation and FosB Expression Are Associated with L-DOPA-Induced Dyskinesia in Hemiparkinsonian Mice. Biol Psychiatry. 59:64-74.
36. Prieto GA, Perez-Burgos A, Palomero-Rivero M, Galarraga E, Drucker-Colin R, Bargas J. 2011. Upregulation of D2-class signaling in dopamine-denervated striatum is in part mediated by D3 receptors acting on Ca V 2.1 channels via PIP2 depletion. J Neurophysiol. 105:2260-2274.
37. Ruiz-DeDiego I, Mellstrom B, Vallejo M, Naranjo JR, Moratalla R. 2015. Activation of DREAM(downstreamregulatory element antagonistic modulator), a calcium-binding protein, reduces LDOPA-induced dyskinesias in mice. Biol Psychiatry. 77:95-105.
38. Santini E, Alcacer C, Cacciatore S, Heiman M, Hervé D, Greengard P, Girault JA, Valjent E, Fisone G. 2009. l DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice. J Neurochem. 108:621-633.
39. Santini E, Valjent E, Usiello A, Carta M, Borgkvist A, Girault JA, Hervé D, Greengard P, Fisone G. 2007. Critical Involvement of cAMP/DARPP-32 and Extracellular Signal-Regulated Protein Kinase Signaling in l-DOPA-Induced Dyskinesia. J Neurosci. 27:6995-7005.
40. Schneider CA, Rasband WS, Eliceiri KW. 2012. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 9:671-675.
41. Silverdale MA, Nicholson SL, Ravenscroft P, Crossman AR, Millan MJ, Brotchie JM. 2004. Selective blockade of D(3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate. Exp Neurol. 188:128-138.
42. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC. 1990. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature. 347:146-151.
43. Solís O, Espadas I, Del-Bel EA, Moratalla R. 2015. Nitric oxide synthase inhibition decreases l-DOPA-induced dyskinesia and the expression of striatal molecular markers in Pitx3(-/-) aphakia mice. Neurobiol Dis. 73:49-59.
44. Suárez LM, Solís O, Caramés JM, Taravini IR, Solís JM, Murer MG, Moratalla R. 2014. L-DOPAtreatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice. Biol Psychiatry. 75:711-722.
45. Thiele SL, Chen B, Lo C, Gertler TS, Warre R, Surmeier JD, Brotchie JM, Nash JE. 2014. Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse models. Neurobiol Dis. 71:334-344.
46. van Kampen JM, Stoessl AJ. 2003. Effects of oligonucleotide antisense to dopamine D3 receptor mRNA in a rodent model of behavioural sensitization to levodopa. Neuroscience. 116:307-314.
47. Visanji NP, Fox SH, Johnston T, Reyes G, Millan MJ, Brotchie JM. 2009. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease. Neurobiol Dis. 35:184-192.
48. Westin JE, Vercammen L, Strome EM, Konradi C, Cenci MA. 2007. Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol Psychiatry. 62:800-810.
49. Xu M, Koeltzow TE, Santiago GT, Moratalla R, Cooper DC, Hu XT, White NM, Graybiel AM, White FJ, Tonegawa S. 1997. Dopamine D3 receptor mutant mice exhibit increased behavioral sensitivity to concurrent stimulation of D1 and D2 receptors. Neuron. 19:837-848.
50. Zhang L, Lou D, Jiao H, Zhang D, Wang X, Xia Y, Zhang J, Xu M. 2004. Cocaine-induced intracellular signaling and gene expression are oppositely regulated by the dopamine D1 and D3 receptors. J Neurosci. 24:3344-3354.